Collecting blood samples from lung cancer patients on targeted therapy
proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors
This study is collecting blood samples from adults with non-small cell lung cancer who are on targeted therapy to see how their treatment is working and to check for any changes in their cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Erasmus Medical Center Academic / other |
| Locations | 1 site (Rotterdam) |
| Trial ID | NCT05221372 on ClinicalTrials.gov |
What this trial studies
This observational study involves adult patients with non-small cell lung cancer (NSCLC) who are being treated with tyrosine kinase inhibitors (TKIs). The study aims to collect repeated blood samples at various intervals during treatment to conduct liquid mutation testing and pharmacokinetic analysis. Blood will be drawn during routine clinical visits, and additional samples will be taken when patients undergo standard biopsies. The goal is to monitor mutations and resistance mechanisms without interfering with standard care practices.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with locally advanced or metastatic NSCLC harboring an oncogenic driver mutation who are starting treatment with a TKI.
Not a fit: Patients who are unable to provide blood samples for study purposes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of resistance mechanisms in lung cancer, leading to more personalized treatment strategies.
How similar studies have performed: Other studies have shown success in using liquid biopsies for monitoring mutations in cancer patients, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Able to understand the written informed and able to give informed consent * Locally advanced or metastatic NSCLC with oncogenic driver mutation * Treatment with TKI according to standard of care Exclusion Criteria: * Unable to draw blood for study purposes
Where this trial is running
Rotterdam
- Erasmus MC — Rotterdam, Netherlands (Recruiting)
Study contacts
- Principal investigator: Anne-Marie Dingemans, MD, PhD — Erasmus Medical Center
- Study coordinator: Anne-Marie Dingemans, MD, PhD
- Email: a.dingemans@erasmusmc.nl
- Phone: +31107040704
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.